SVF
Level A· Stronger Clinical EvidenceSystematic Review

The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.

Navarro-Garcia de Llano JP., Sanchez-Garavito JE., Iyer H., Fuentes-Tapias S., Safa A., Michaelides L.

Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Systematic Review
Journal
Neurosurg Rev (2026)
Country
Germany
Reported sample size
8
PMID
41578017
DOI
10.1007/s10143-025-04075-y

Abstract (original English)

Trigeminal neuralgia (TN) is a neuropathic pain disorder characterized by severe orofacial pain. The underlying pathophysiological nuances remain under study, and their understanding is key to developing new and more effective therapies for this debilitating disease. The field of cellular therapies for neurological diseases is continuously evolving. This systematic review was performed after the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. We sought studies on the preclinical and clinical uses of cellular therapies for trigeminal neuralgia. We included 8 studies encompassing 1 clinical and 7 preclinical applications. Of the preclinical studies, four used Stem Cells from Human Exfoliated Deciduous Teeth (SHED), two used Olfactory Ensheathing Cells (OECs), and one used Bone Marrow Mesenchymal Stem Cells (BMSCs). All preclinical studies showed a statistically significant behavioral improvement in groups receiving cellular therapies compared to controls (p < 0.05), with either local or systemic delivery. In addition, cellular therapies have the potential to mitigate TN by promoting myelin repair, reducing neuroinflammation, and modulating pain-related pathways. The only clinical report in the literature described the incidental use of Adipose-Derived Stem Cells (ADSCs) during a facial cosmetic procedure in a 60-year-old female with a long history o

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansTrigeminal NeuralgiaAnimalsCell- and Tissue-Based TherapyMesenchymal Stem Cell TransplantationTreatment OutcomeStem Cell Transplantation
Face & SkinSystemic / IVNeuroinflammation
View on PubMedDOI

Related research